173 related articles for article (PubMed ID: 8679055)
1. Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
Gupta R; al-Said NH; Oreski B; Lown JW
Anticancer Drug Des; 1996 Jun; 11(4):325-38. PubMed ID: 8679055
[TBL] [Abstract][Full Text] [Related]
2. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
3. Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin.
Henichart JP; Waring MJ; Riou JF; Denny WA; Bailly C
Mol Pharmacol; 1997 Mar; 51(3):448-61. PubMed ID: 9058600
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
Zhao R; al-Said NH; Sternbach DL; Lown JW
J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
6. DNA binding properties of minor groove binders and their influence on the topoisomerase II cleavage reaction.
Bell A; Kittler L; Löber G; Zimmer C
J Mol Recognit; 1997; 10(6):245-55. PubMed ID: 9770648
[TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
Vashisht Gopal YN; Jayaraju D; Kondapi AK
Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
[TBL] [Abstract][Full Text] [Related]
9. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
11. Antitumor agents. Part 227: Studies on novel 4'-O-demethyl-epipodophyllotoxins as antitumor agents targeting topoisomerase II.
Xiao Z; Bastow KF; Vance JR; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3339-44. PubMed ID: 15158802
[TBL] [Abstract][Full Text] [Related]
12. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, DNA-binding and cytotoxic properties of a bis(netropsin)-anthracenedione conjugate.
Boitte N; Pommery N; Colson P; Houssier C; Waring MJ; Hénichart JP; Bailly C
Anticancer Drug Des; 1997 Sep; 12(6):481-501. PubMed ID: 9311557
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
Kamal A; Atchison K; Daneshtalab M; Micetich RG
Anticancer Drug Des; 1995 Oct; 10(7):545-54. PubMed ID: 7495478
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of the novel DNA topoisomerase II inhibitors: esterification and amination substituted 4'-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways.
Xiao L; Zhao W; Li HM; Wan DJ; Li DS; Chen T; Tang YJ
Eur J Med Chem; 2014 Jun; 80():267-77. PubMed ID: 24793877
[TBL] [Abstract][Full Text] [Related]
16. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
17. Antitumor agents. 164. Podophenazine, 2'',3''-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors.
Cho SJ; Kashiwada Y; Bastow KF; Cheng YC; Lee KH
J Med Chem; 1996 Mar; 39(7):1396-402. PubMed ID: 8691469
[TBL] [Abstract][Full Text] [Related]
18. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
[TBL] [Abstract][Full Text] [Related]
19. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition.
Krishnan P; Bastow KF
Anticancer Drug Des; 2000 Aug; 15(4):255-64. PubMed ID: 11200501
[TBL] [Abstract][Full Text] [Related]
20. Aromatic analogues of DNA minor groove binders--synthesis and biological evaluation.
Pućkowska A; Bielawski K; Bielawska A; Midura-Nowaczek K
Eur J Med Chem; 2004 Jan; 39(1):99-105. PubMed ID: 14987838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
